Sharp Therapeutics (TSXV:SHRX) Total Equity: C$-0.24 Mil (As of Dec. 2025)


TSXV:SHRX Sharp Therapeutics Corp TSXV:SHRX
15 GF Score
Price C$0.91
View Full Analysis

What is Sharp Therapeutics Total Equity?

Sharp Therapeutics TSXV:SHRX 15 Total Equity is C$-0.24 Mil as of Dec. 2025. GuruFocus rates TSXV:SHRX with a GF Score™ of 15/100.

Sharp Therapeutics's total equity for the quarter that ended in Dec. 2025 was C$-0.24 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Sharp Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Sharp Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sharp Therapeutics Total Equity Chart

Sharp Therapeutics Annual Data
Trend Dec23 Dec24 Dec25
Total Equity
-15.40 3.68 -0.24

Sharp Therapeutics Quarterly Data
Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only 3.68 -0.95 3.36 1.96 -0.24
TSXV:SHRX
15GF Score
Sharp Therapeutics Corp TSXV:SHRX
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sharp Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Sharp Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2.693-2.937
=-0.24

Sharp Therapeutics's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2.693-2.937
=-0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of C$-0.24 Mil mean?
Sharp Therapeutics (TSXV:SHRX) has a Total Equity of C$-0.24 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Sharp Therapeutics and its competitors.
Is Sharp Therapeutics' Total Equity too high?
Sharp Therapeutics' current Total Equity is C$-0.24 Mil. Overall, Sharp Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Total Equity compare to VRTX and REGN?
Sharp Therapeutics' Total Equity of C$-0.24 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Sharp Therapeutics and its competitors. Sharp Therapeutics's current Total Equity is C$-0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Total Equity of C$-0.24 Mil. The current Total Equity is C$-0.24 Mil. Sharp Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Total Equity is C$-0.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sharp Therapeutics Business Description

Address 2403 Sidney Street, Suite 264, Pittsburgh, PA, USA, 15203
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score

Get the complete analysis for TSXV:SHRX

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$0.91
Price